Project Grant R01CA311503
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $623K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $608,558 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Research Institute at Nationwide Children's Hospital, effective April 2, 2026 through March 31, 2031. This award supports fundamental research to genetically and metabolically define high-risk neuroblastoma and develop novel therapeutic strategies. The project addresses critical gaps in understanding neuroblastoma oncogenesis and treatment, focusing on...
- Federal Grant Award Summary The National Cancer Institute awarded The Children's Hospital of Philadelphia Research Institute a $457,683 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. This research initiative focuses on developing and optimizing macromolecular prodrug-based drug delivery systems to enhance the efficacy of SN-38 (a topoisomerase I inhibitor) against high-risk neuroblastoma, the most common and deadly solid...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute awarded Children's Research Institute a Project Grant of $467,968 under the Cancer Treatment Research program (CFDA 93.395) to conduct research evaluating the synergistic therapeutic effects of retinoic acid and proteasome inhibitors in neuroblastoma treatment. The grant period runs from June 1, 2026 through May 31, 2028. The primary deliverable is a systematic evaluation of combination therapy approaches using three proteasome inhibitors...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning March 13, 2026, with completion targeted for February 28, 2029. This award supports the development and application of high-throughput tools designed to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events that drive oncogenic mechanisms...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $767,328 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025 through July 31, 2030. The award funds research to investigate targeting splicing vulnerabilities in neuroblastoma, a malignancy responsible for 15% of childhood cancer-related deaths. The research will evaluate the efficacy and mechanisms of indisulam, a molecular glue...
- The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $707,798 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-refractory form shortly after...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- The National Cancer Institute awarded a $922,755 Cooperative Agreement to the University of Massachusetts Medical School effective August 28, 2025, through July 31, 2030, under the Cancer Biology Research program (CFDA 93.396). The project will investigate tRNA (transfer RNA) modification reprogramming and translational remodeling in cancer, with a primary focus on melanoma progression and metastasis. The research will employ RNA mass spectrometry, sequencing approaches, and enhanced ribosome...